Author + information
- J.L. Martínez-Sande,
- J. García-Seara,
- L. González-Melchor,
- M. Rodríguez-Mañero,
- X.A. Fernández-López,
- D. Iglesias-Alvarez,
- V. González-Salvado and
- J.R. González-Juanatey
Currently, studies on the leadless pacemaker (Micra) have mostly been limited to clinical trials with less than 6 months’ follow-up and they often fail to reflect real population outcomes. We sought to evaluate electrical parameters at implantation and during follow-up, as well as the safety of this new technique.
This prospective, observational study included 74 consecutive patients, all ≥ 65 years, with an indication for single-chamber pacemaker implantation. Mean follow-up period was 8,9 ± 8,4 months.
Successful implantation was accomplished in all patients referred for leadless implantation. The mean age was 79-0 ± 7.1 years (range, 66-89 years); 44 (58,7%) were men and 54 had permanent atrial fibrillation (89.2%).Concomitant atrioventricular node ablation was performed immediately after implantation in 15 patients (20.3%). The procedure was performed under an uninterrupted anticoagulation in 58 patients (78.4%). With the exception of 1 femoral arteriovenous fistula and 1 with cardiac tamponade, there were no others complications. In both cases was required surgical repair whom were discharged successfully. Sensing and pacing parameters were stable both at implantation and during the mid-term follow-up. Table 1.
|Implant (n=74)||Predischarge (n=74)||1 month (n=54 )||3 months (n= 52)||6 months (n= 42)||12 months (n=26)|
(V a 0.24 ms)
|R wave (mV)||12.0±4,8||13.1±5.0||14.2±4.9||13.9±4.6||14.4±4.6||15.3±4.8|
Implantation of leadless pacemakers is feasible, safe and provides advantages over the conventional system. Further studies with longer follow-up periods will be needed before these devices become widely used in routine clinical practice.